NASDAQ:REPH - Recro Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0.30 (1.20%)
Get New Recro Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for REPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for REPH

Analyst Price Target is $0.00
This price target is based on 1 analysts offering 12 month price targets for Recro Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for REPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Recro Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/28/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/28/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/12/2021William BlairInitiated CoverageOutperformMedium
1/4/2021Craig HallumInitiated CoverageBuyN/A
5/12/2020OppenheimerLower Price TargetOutperform$18.00 ➝ $12.00High
3/5/2020StephensLower Price TargetOverweight$19.00 ➝ $18.00Low
11/26/2019StephensLower Price TargetOverweight$23.00 ➝ $19.00Low
11/12/2019StephensBoost Price Target$17.00 ➝ $23.00Low
10/16/2019StephensInitiated CoverageOverweight$14.00High
8/9/2019OppenheimerSet Price TargetBuy$20.00Medium
4/4/2019OppenheimerBoost Price TargetOutperform$9.00 ➝ $15.00Medium
3/25/2019OppenheimerReiterated RatingOutperform$19.00 ➝ $9.00High
3/25/2019Roth CapitalReiterated RatingBuy ➝ Neutral$15.00 ➝ $7.50N/A
2/20/2019OppenheimerSet Price TargetBuy$18.00Medium
1/31/2019Janney Montgomery ScottReiterated RatingBuy ➝ Buy$13.00High
11/8/2018Piper Jaffray CompaniesSet Price TargetBuy$10.00Low
11/8/2018OppenheimerSet Price TargetBuy$18.00N/A
10/1/2018Janney Montgomery ScottSet Price TargetBuy$13.00Low
9/5/2018OppenheimerSet Price TargetBuy$18.00High
8/8/2018OppenheimerSet Price TargetBuy$18.00High
5/26/2018Roth CapitalSet Price TargetBuy$9.00Low
5/25/2018OppenheimerSet Price TargetBuy$18.00High
5/24/2018Piper Jaffray CompaniesLower Price TargetOverweight$17.00 ➝ $9.00High
5/24/2018Janney Montgomery ScottLower Price TargetBuy ➝ Fair Value$21.00 ➝ $11.00High
4/19/2018Berenberg BankInitiated CoverageBuyLow
4/5/2018OppenheimerReiterated RatingBuyHigh
3/23/2018OppenheimerReiterated RatingBuyMedium
2/28/2018OppenheimerSet Price TargetBuy$19.00High
2/14/2018CIBCInitiated CoverageOutperform ➝ Outperform$19.00High
2/13/2018UBS GroupInitiated CoverageOutperformHigh
2/13/2018OppenheimerInitiated CoverageOutperform$19.00High
10/27/2017Piper Jaffray CompaniesReiterated RatingBuy$11.00N/A
7/31/2017Roth CapitalSet Price TargetBuy$20.00Low
7/25/2017Piper Jaffray CompaniesSet Price TargetBuy$11.00High
6/14/2017Janney Montgomery ScottDowngradeBuy ➝ Fair Value$21.00 ➝ $6.50High
(Data available from 5/28/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/30/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
12/29/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/28/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/27/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/29/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/28/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/28/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Recro Pharma logo
Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $1.73
Low: $1.47
High: $2.11

52 Week Range

Now: N/A

Volume

141,800 shs

Average Volume

126,298 shs

Market Capitalization

$117.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08

Frequently Asked Questions

What sell-side analysts currently cover shares of Recro Pharma?

The following sell-side analysts have issued research reports on Recro Pharma in the last year: StockNews.com, William Blair, and Zacks Investment Research.
View the latest analyst ratings for REPH.

What is the current price target for Recro Pharma?

0 Wall Street analysts have set twelve-month price targets for Recro Pharma in the last year.
View the latest price targets for REPH.

What is the current consensus analyst rating for Recro Pharma?

Recro Pharma currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe REPH will outperform the market and that investors should add to their positions of Recro Pharma.
View the latest ratings for REPH.

How do I contact Recro Pharma's investor relations team?

Recro Pharma's physical mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The specialty pharmaceutical company's listed phone number is (770) 534-8239 and its investor relations email address is [email protected] The official website for Recro Pharma is www.recropharma.com. Learn More about contacing Recro Pharma investor relations.